SANTÉ

Attending the #BostonCEO event by @Longwood Healthcare Leaders this year? If so, come hear Omar H. Khalil who will be closing out day 1 with a panel discussion on October 28th.   Omar’s session, “Structuring the Syndicate,” will be at 4:40pm and will feature perspectives from top life sciences investors on how to assemble the most effective syndicates for today’s market.   Find more information on registration here: https://lnkd.in/eehfZ2xB   #VentureCapital #Biotech

Congratulations to @Endogenex who just completed their first patient enrollment in the ReCET Clinical Study. This is a major milestone, which will help address the root causes of type 2 diabetes.   Previous treatments have failed to adequately manage blood glucose levels - leaving millions of patients at higher risk of complications. Endogenex’s ReCET™ system works to reset the body’s natural metabolic processes, offering a more targeted treatment instead of symptom management.   @Santé is proud to support companies like Endogenex who are creating innovative approaches to improving healthcare and changing the way we think about this disease.   https://lnkd.in/eNGKApNt

Congratulations to Sergio Santillana on your new position as Chief Medical Officer! We are very excited to be a part of the Solu Therapeutics journey, and look forward to our continued work together.

Congratulations to @DanRose on becoming the new CEO of @EndovascularEngineering! We’re inspired by all that EE has accomplished these past few years, and we look forward to our continued work together developing and deploying the innovative Hēlo Thrombectomy System. More details on Dan and the novel Hēlo technology in this week’s release. https://lnkd.in/e8pEFmdb

Historically, the venture capital industry has overlooked weight-loss solutions – but the advent of GLP-1 medications has changed the landscape rapidly over the past few years.   Dennis McWilliams shares his perspective on the shift towards these treatments in a new Bloomberg article, highlighting recent developmental efforts to produce options with more tolerable side effects. Additionally, as patients often regain weight after stopping these drugs, companies are looking to create new strategies in managing this transition without rebounding.   While it seems that every major pharma company now has their own obesity strategy, Dennis provides thoughts on where to invest in what has become a crowded market.   https://lnkd.in/eHSqdsAG

We’re proud to play a role in the growth of @Endogenex – who this week announced an $88M Series C round! Endogenex is pioneering new approaches to treating patients with Type 2 diabetes, by resetting the body’s metabolic signaling system. The company developed an innovative ReCET System that applies precise, controlled, and non-thermal pulsed electric fields to help patients regain control of their blood glucose levels and slow disease progression. It’s a novel solution with significant promise for patients struggling with this disease. Congrats to the full team on your continued success. https://lnkd.in/eCrU2nyb

Congratulations to the full team at @GlyscendTherapuetics on today’s announcement!   The initiation of phase 2 clinical trials on GLY-200, a novel oral treatment for obesity, mark a big step forward in obesity treatment. Glyscend’s innovative approach mimics the effects of bariatric surgery with an oral drug, requiring far less of a burden on patients.   Millions of people living with obesity and type 2 diabetes, who have so far had to rely on surgery or injection treatments, will (hopefully) be able to benefit from this approach in the future. It’s one of the reasons we are proud to work with companies like Glyscend who are truly moving the needle and changing the way we think about healthcare.

The 23rd annual Medtech MVP Conference is taking place June 17-18 this year in Minneapolis, and James Eadie, Managing Director will be joining the discussion.   James will be on a panel covering the Clinical and Regulatory Strategies for Commercial Success, along with Margot G., Chief Medical Officer, SpyGlass Pharma, Sam Roosz, CEO, Crescendo Health, and Stacey Pugh CEO, Endogenex.   Even the most innovative treatments cannot impact the healthcare system if they don’t have a viable path to commercial success. This will be a great conversation on strategies to keep in mind throughout a company’s growth, and what to do when things don’t go according to plan.   If you’ll be at this year’s event, come hear the panel at 2:10 on June 18th.   https://lnkd.in/e7Uuvt6h

Congratulations to the team at Endovascular Engineering on today’s announcement!   The firm, which is pioneering the advancement of clot removal technologies for venous thromboembolism (VTE), shared positive safety and feasibility results from its ENGULF US clinical trial. This trial is a prospective, multi-center, feasibility study evaluating the safety and performance of the Hēlo™ PE Thrombectomy System for treating acute pulmonary embolism (PE). It was conducted under an FDA IDE.   As Mike Rosenthal, CEO of Endovascular Engineering notes, the Hēlo System is a purpose-built platform for the treatment of PE and is “now supported by more clinical evidence than any other emerging company.”   More details on the study and the outcome can be found in the press release below.   https://lnkd.in/gJbcXEy5

Excited to announce that Dennis McWilliams will be joining a discussion at the American Urological Association (AUA) conference in San Antonio this Thursday, May 2nd!   The panel promises to be an insightful conversation on the latest opportunities, challenges, and trends in the field of urology from an investor's perspective. Drawing from his years of experience as both an investors as well as a founder, Dennis will be sharing valuable perspectives on the developments that are shaping the future of this field.   More info on the agenda, registration, and other speakers can be found here: https://bit.ly/3xydmx6